Trial Profile
A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nesolicaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; First in man
- Sponsors Proteostasis Therapeutics
- 23 May 2018 Results assessing the relationship between nasal CFTR protein levels with lung function changes in response to lumacaftor-ivacaftor treatment for Phe508del homozygous CF patients, presented at the 114th International Conference of the American Thoracic Society
- 20 Mar 2018 According to a Proteostasis Therapeutics media release, based on the data from this trial, triple combination study (see profile 292094 ) protocol received endorsement and a high strategic fit score from the Therapeutics Development Network (TDN) and the Clinical Trial Network (CTN) in January 2018.
- 14 Mar 2018 Results published in the Proteostasis Therapeutics media release.